Avastin (bevacizumab) for brain cancer has no fixed endpoint. The standard approach is to continue treatment for as long as it’s working, stopping only when the tumor starts growing again or side effects become too severe. Some patients stay on it for months, others for a year or more, but the median duration before the cancer progresses is roughly 3.5 months for recurrent glioblastoma, the most common and aggressive form of brain cancer.
Why There’s No Set Time Limit
Unlike some cancer treatments given in a defined number of rounds, Avastin is prescribed on a “treat to progression” basis. You receive infusions every two weeks (at 10 mg/kg) or every three weeks (at 15 mg/kg), and your oncology team monitors you with regular brain MRIs to check whether the drug is still controlling the tumor. As long as scans look stable and you’re tolerating the treatment, infusions continue. In clinical trials, some protocols allowed treatment for up to 104 weeks (two years), though most patients don’t remain on it that long because the cancer eventually finds a way to grow despite the drug.
What Avastin Actually Does in the Brain
Avastin works differently from traditional chemotherapy. It doesn’t kill tumor cells directly. Instead, it blocks a protein called VEGF-A that brain tumors use to build new blood vessels and feed themselves. By cutting off that supply line, the drug prunes the small, chaotic blood vessels that tumors generate, reducing overall vessel density inside the tumor over time. The surviving blood vessels reorganize into a more normal pattern with less leakage.
That anti-leakage effect is especially important in the brain. Glioblastoma vessels are abnormally “leaky,” allowing fluid to seep into surrounding brain tissue and cause swelling (edema). Avastin significantly reduces that permeability, which is why many patients notice a rapid improvement in neurological symptoms like headaches, weakness, or confusion within the first few infusions. This benefit often occurs before the tumor itself has meaningfully shrunk.
One complication of this mechanism: because Avastin reduces vessel leakage, contrast-enhanced MRI scans can look dramatically better even when the underlying tumor hasn’t changed much. Your care team uses specialized criteria that also evaluate non-enhancing areas on MRI to get a more accurate picture of what’s really happening.
How Long It Typically Controls the Tumor
For recurrent glioblastoma, the most studied setting for Avastin in brain cancer, the median progression-free survival on the drug is about 3.5 months. That means half of patients see the tumor held in check for longer than 3.5 months, and half for less. Median overall survival from the start of Avastin treatment runs around 10 months.
These are median figures, so individual experiences vary considerably. Some patients respond strongly and remain on treatment for six months to a year or longer. Others show progression within weeks. Your response depends on factors like tumor genetics, how much disease is present when you start, and your overall health. People who show a clear response on imaging (tumor shrinkage or significant stabilization) tend to have longer durations on the drug.
Reducing Steroid Dependence
Many brain cancer patients take corticosteroids to manage brain swelling, but long-term steroid use carries its own problems: weight gain, muscle weakness, high blood sugar, and immune suppression. Because Avastin directly reduces tumor-related swelling, it often allows patients to cut back or stop steroids entirely. In one major study, about 30 to 47 percent of patients on Avastin achieved a sustained steroid dose reduction of at least 50 percent, and roughly 16 to 21 percent were able to discontinue steroids completely for a meaningful portion of their treatment. For many patients, this improvement in quality of life is one of the most tangible benefits of the drug.
What Happens When You Stop
A common concern is whether stopping Avastin triggers a dangerous “rebound” of rapid tumor growth or sudden brain swelling. Research on patients who discontinued the drug early found no definite rebound phenomenon. In one study, the median time from stopping Avastin to tumor progression was about 11 weeks, and for patients who had responded well to treatment, that window extended to roughly 13 weeks. Survival after discontinuation was similar regardless of whether patients stopped the drug early or continued until full progression.
That said, outcomes after stopping Avastin are generally poor because most patients discontinue it precisely because the tumor is advancing. The median time from Avastin discontinuation to death in one study was about 28 weeks (roughly seven months). This reflects the aggressive nature of recurrent glioblastoma rather than a harmful effect of stopping the drug itself.
Reasons Treatment Ends
Your oncologist will stop Avastin for one of two main reasons. The first is disease progression: MRI scans show a 25 percent or greater increase in the enhancing tumor area, new lesions appear, or there’s a significant expansion of abnormal signal in the surrounding brain tissue. The second is unacceptable side effects. Avastin can cause high blood pressure, protein in the urine, blood clots, impaired wound healing, and in rare cases, bleeding in the brain or gastrointestinal tract. If any of these become serious enough, the risk of continuing outweighs the benefit.
Some patients also stop because their functional status declines to the point where the burden of traveling for infusions every two to three weeks no longer makes sense. These are deeply individual decisions made in conversation with the care team, and there’s no single “right” duration that applies to everyone.